Oxford BioDynamics takes prostate cancer test to UAE via Dubai partnership Oxford BioDynamics has signed a partnership to offer its EpiSwitch PSE prostate cancer test across the United Arab Emirates, its…
Oxford BioDynamics shares surge after landing first paying customer for Orion genomics platform Oxford BioDynamics has signed the first commercial agreement for its EpiSwitch Orion platform, marking the first time an outside party…
AIM movers: Celsius Resources selling Namibian asset new boss for Oxford BioDynamics Celsius Resources (LON: CLA) has executed a binding sale agreement with Chinalco (Xiong’an) Mining Corporation for the disposal of 95% of…
Oxford BioDynamics shares soar 33% after unveiling breakthrough blood test for Chronic Fatigue Syndrome Oxford BioDynamics PLC (AIM:OBD, OTC:OXBOF) shares surged 33% on Wednesday after the company announced it had developed a highly accurate…
Oxford BioDynamics unveils blood test for Chronic Fatigue Syndrome with 96% accuracy Oxford BioDynamics PLC (AIM:OBD, OTC:OXBOF) has developed what it calls a “first-in-class” blood test to diagnose Chronic Fatigue Syndrome, a…
AIM weekly movers: Oxford BioDynamics gains recognition from Pfizer trial Oil and gas producer Empyrean Energy (LON: EME) says the operator of the Mako field has signed a gas sales…
AIM movers: Pfizer confirms efficacy of Oxford BioDynamics EpiSwitch and Sosandar write down reduces profit Oxford BioDynamics (LON: OBD) says Pfizer has published information on its use of EpiSwitch biomarkers as a liquid biopsy in…
AIM movers: Hornby leaving AIM and ex-dividends Ethernity Networks (LON: ENET) has invoiced $890,000 of a $1.05m contract with a US aerospace system products provider. The contract…